Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The top half of the image is the Exogene logo on a pastel rainbow background. The lower half of the image is the KQ Labs logo and the Frances Crick Institute logo on a black background.

Exogene is excited to join the KQ Labs five-month accelerator programme. The programme is for exciting early-stage startups using data as a core part of their business model to improve human health, run by the Francis Crick Institute and funded by the medical research charity LifeArc in partnership with Cancer Research UK and UK SPINE.The programme is aimed at accelerating early-stage start-ups and providing training to create future leaders. A key ambition is to catalyse the development of a data-driven health ecosystem in the UK, validating new ideas and putting exciting companies on the path to receiving further investment.


The new cohort, consisting of companies looking to tackle health challenges and diseases including diabetes, cancer and multiple sclerosis, will also benefit from funding in the form of a convertible loan, and introductions to key investors and major corporates. 


Exogene is an early-stage biotechnology startup enabling the discovery of T-cell-receptor (TCR)-based cell therapies to tackle solid cancers and reverse immune ageing, by combining artificial intelligence (AI) and high-throughput TCR screening in the lab. The company joined the BioEscalator community in June 2021. Its team is building an AI platform to computationally screen entire patient-derived TCR repertoires and identify rare, effective TCRs for cell therapy applications. 


Find out more 

Original article